|
Published
|
Volume-Issue
|
Title
|
Total: 112 |
01/2009 |
13-8 |
Clopidogrel Resistance
By AWAD A.R. ALQAHTANI, MD, FRCPC, and GORDON MOE, MD, FRCPC
Antiplatelet therapy is a cornerstone of cardiovascular (CV) medicine, and acetylsalicylic acid (ASA) and clopidogrel have emerged as critical therapies in the treatment of CV disease. Despite their efficacy, patients on these medications continue to experience adverse clinical events. In fact, millions of patients are currently on low-dose antiplatelet therapy, but it is unknown how many of these patients are undertreated or on the wrong medication.
|
12/2008 |
13-9 |
Diet and Cardiovascular Disease: A Complex Relationship
By DARREN KAGAL, MD, FRCPC, and BETH ABRAMSON, MD, FRCPC, FACC
It is well known that diet has an impact on cardiovascular disease (CVD); however, it is unclear whether the effect of diet is solely due to its influence on underlying cardiac risk factors or to other mechanisms. This issue of Cardiology Rounds explores the complex relationship between dietary intake and overall CV risk.
|
12/2008 |
13-7 |
Omega-3 Polyunsaturated Fatty Acids (Fish Oils) and Heart Disease – Clinical Benefit or Just a Fad?
By PAUL DORIAN, MD, and ANDREW RAMADEEN, BSc
The effect of marine-derived fish oils (omega-3 [?-3] polyunsaturated fatty acids [PUFAs]) on human health and disease continues to fascinate researchers in many disciplines. A PubMed search (http://www.ncbi.nlm.nih.gov/sites/entrez) in July 2008 revealed a total of 11,000 articles relating to the effects of “PUFAs, EPA, or DHA” on health.
|
11/2008 |
13-6 |
Evidence-based Management of Pulmonary Hypertension
By DOUGLAS NG, MD, and GORDON MOE, MD, FRCPC
Pulmonary-arterial hypertension (PAH) from any cause is more prevalent than previously believed, and significant uncertainties remain regarding the diagnosis and optimal treatment of PAH. It is now recognized that effective treatment for one cause of PAH may not necessarily be useful for PAH from a different cause. This issue of Cardiology Rounds reviews the contemporary definition, classification, and diagnosis of PAH, with a focus on recent developments in its treatment.
|
09/2008 |
13-5 |
Vascular protection update 2008: the ONTARGET study
By BETH L. ABRAMSON, MD, FRCPC, FACC
The renin-angiotensin-aldosterone system (RAAS) is a hormonal system that regulates blood pressure (BP) and fluid balance; it constitutes an area of important research interest in the management of cardiovascular disease (CVD). This issue of Cardiology Rounds reviews the concept of vascular protection via renin-angiotensin system (RAS) blockade, as well as the clinical trial data to date supporting this concept.
|
05/2008 |
13-4 |
An Overview of Atrial Fibrillation
After Cardiac Surgery
By AWAD A. ALQAHTANI, MD, FRCPC, and GORDON MOE, MD, FRCPC
Postoperative atrial fibrillation (POAF) is a common complication of cardiac surgery and is associated with an increased incidence of other complications (eg, postoperative stroke), increased hospital length of stay, and increased costs of hospitalization. Prevention of AF is a reasonable clinical goal and, consequently, many randomized trials have evaluated the effectiveness of pharmacological and nonpharmacological interventions.
|
05/2008 |
13-3 |
Isolated Ventricular Noncompaction:
A New Cardiomyopathy
By PAALADINESH THAVENDIRANATHAN, MD, MSc, FRCPC, and CHI-MING CHOW, MDCM, MSc, FRCPC, FACC
Isolated ventricular noncompaction (IVNC) is a rare congenital disorder that was first described in a 33-year-old woman by Engberding et al, in 1984. Subsequently, many case reports and several case series in both children and adults have been published.
|
04/2008 |
13-2 |
Stroke Prophylaxis in Non-Valvular Atrial Fibrillation
By BRIAN K. COURTNEY, MD, MSEE, and PAUL DORIAN, MD, FRCPC
Atrial fibrillation (AF) is the most common cardiac arrhythmia; lifetime risk for the development of AF is 1 in 4 in people 40 years of age and older. AF is also a powerful and independent risk factor for stroke. The availability of oral anticoagulation agents, such as warfarin or other vitamin K antagonists, provides a substantial opportunity to reduce the relative risk of stroke or other cardioembolic events by >60%.
|
03/2008 |
13-1 |
Alcohol and Cardioprotection – Reality or Observational Mistake?
By AKSHAY BAGAI, MD, FRCPC, and BETH ABRAMSON, MD, MSc, FRCPC, FACC
Excessive chronic consumption of alcohol is a significant cause of morbidity and premature mortality. In contrast, an extensive body of scientific evidence indicates that drinking alcohol in moderation on a daily basis appears to offer protection against disease of the heart and the vascular system. This U-shaped alcohol-mortality relationship, in which mortality risk increases among abstainers and heavy drinkers relative to light or moderate drinkers has been observed since the 1980s.
|
12/2007 |
12-10 |
Universal Definition of Myocardial Infarction
By TONY C. LEE, MD, MSc, and JUAN CARLOS MONGE, MD, FRCPC
Coronary artery disease is a major cause of morbidity and mortality worldwide. During the natural progression of atherosclerotic plaque, an abrupt and potentially catastrophic event may occur, namely plaque disruption, leading to exposure to substances that promote platelet activation and aggregation, and subsequently thrombin formation.
|
11/2007 |
12-9 |
Ultrafiltration in Acute Decompensated
Heart Failure
By WAIL ALKASHKARI, MD, and GORDON MOE, MD
Acute heart failure is a major clinical and public health problem. Advanced refractory heart failure represents an important subgroup of patients presenting with acute heart failure syndrome. Fluid congestion is a hallmark in patients with advanced heart failure, and resistance to pharmacologic therapy – particularly diuretics – frequently develops as the disease progresses.
|
10/2007 |
12-8 |
Endothelial Shear Stress:
Impact on Atherosclerosis
By ANTONIO ROCCA MD, PhD, FRCPC and JUAN CARLOS MONGE MD, FRCPC
Atherosclerosis, a disease that can have devastating consequences, afflicts a large proportion of people in the industrialized world and, increasingly, in developing countries as well. Atherosclerosis is a chronic inflammatory condition of large- and medium-sized vessels that has serious consequences on the cardiovascular (CV) system, leading to the development of myocardial infarction (MI) and stroke.
|
09/2007 |
12-7 |
Exercise and Acute Cardiovascular Events
By SEAN JEDRZKIEWICZ, MD, and GORDON MOE, MD
The benefits of regular physical activity in protecting against the manifestations of coronary heart disease (CHD) have been accepted, in part due to data from basic research, as well as from clinical and epidemiologic studies. As clinicians, we encourage our patients to pursue an exercise regimen with at least 20-30 minutes of moderately intense activity on most, if not all, days of the week.
|
08/2007 |
12-6 |
Infective Endocarditis Prophylaxis:
Update for 2007
By JEREMY EDWARDS, MD, HOWARD LEONG-POI, MD, FRCPC
The prevention of infective endocarditis (IE) is a topic that attracts much interest and contention. A recent update of the guidelines for prevention of IE by the American Heart Association (AHA) represents substantial alterations to prior recommendations that had previously become standard practice.
|
06/2007 |
12-5 |
An Overview Of Cardiac Sarcoidosis
By FAHAD BASLAIB MD, FRCPC and GORDON MOE MD, FRCPC
Sarcoidosis, a multisystem disorder affecting individuals worldwide, is pathologically characterized by the presence of noncaseating granulomas in involved organs. Although environmental and genetic factors have been implicated in its pathogenesis, the etiology of cardiac sarcoidosis remains obscure.
|
05/2007 |
12-4 |
Trastuzumab and Heart Failure
By WENDY TSANG, MD, and GORDON MOE, MD, FRCPC, FACC
Trastuzumab is a life-saving therapy in the treatment of breast cancer. However, its use is associated with the development of systolic dysfunction in 5% of patients and approximately 2% of these patients will develop symptomatic congestive heart failure.
|
04/2007 |
12-3 |
Iron-overload Cardiomyopathy Associated with Iron-overload Conditions: Incidence, Pathophysiology, and Treatment
By GAVIN Y. OUDIT, MD, PhD, FRCPC, and GORDON MOE, MD, FRCPC
The prevalence of primary (hereditary) hemochromatosis and secondary iron-overload (hemosiderosis) is reaching epidemic levels worldwide. Iron-overload leads to excessive iron deposition in a wide variety of tissues, including the heart and endocrine tissues. Chronically elevated cardiac iron concentrations impair diastolic function, increase the propensity for arrhythmias and, ultimately, cause end-stage dilated cardiomyopathy.
|
03/2007 |
12-2 |
Fabrys Cardiomyopathy: Diagnosis, Pathophysiology and the Role of Enzyme Replacement Therapy
By GAVIN Y. OUDIT, MD, PhD, FRCPC, ROBERT M. IWANOCHKO, MD, FRCPC, FACC, and GORDON MOE, MD, FRCPC, FACC
Fabry disease is an X-linked abnormality of glycosphingolipid metabolism that results in systemic deposition of sphingolipid, especially in the vascular endothelium and myocardium, which leads to left ventricular hypertrophy (LVH), endothelial dysfunction, and valvular disease.
|
01/2007 |
12-1 |
Diastolic Heart Failure: An Update for 2007
By SACHA BHATIA, MD, and HOWARD LEONG-POI, MD, FRCPC
Heart failure (HF) is currently the most common primary diagnosis in hospitalized patients in the United States and an increasing cause of mortality and morbidity in the North American population. Traditionally, HF has been described as a clinical syndrome associated with impaired myocardial contractility and left ventricular (LV) cavity dilation.
|
12/2006 |
11-10 |
The Metabolic Syndrome:
A Growing Concern
By MARC ALLARD, MD, and GORDON MOE, MD
The metabolic syndrome has become a commonly discussed medical problem and a growing topic of interest for both researchers and the pharmaceutical industry. This issue of Cardiology Rounds discusses the concept of the metabolic syndrome, reviews the various definitions used to diagnose it, and describes risk factors associated with its development and the proposed mechanisms underlying these metabolic risk factors.
|
11/2006 |
11-9 |
Primary Cardiac Tumours
By HANI AMAD, MD, FRCPC, and HOWARD LEONG-POI, MD, FRCPC
Primary cardiac tumours are extremely rare. In most autopsy series, they have an incidence of approximately 0.1% and are far less common than secondary tumours that metastasize to the heart that are reported to be 20 times more common.
|
10/2006 |
11-8 |
Arrhythmogenic right ventricular cardiomyopathy not just a matter of fat
By SHELDON M. SINGH, MD, FRCPC and GORDON W. MOE, MD, FRCPC
Arrhythmogenic right ventricular cardiomyopathy (ARVC), also known as arrhythmogenic right ventricular dysplasia, is an inherited cardiomyopathy associated with arrhythmia, heart failure, and sudden cardiac death (SCD). Considerable strides have been made in understanding the pathogenesis, genetics, and diagnosis of ARVC, since it was first described over 20 years ago.
|
09/2006 |
11-7 |
Microvolt T-Wave Alternans for Sudden Death Risk Stratification in Congestive Heart Failure
By PAUL GALIWANGO, MD, and GORDON MOE, MD
Various studies have demonstrated that automatic implantable cardioverter-defibrillators (ICDs) reduce the risk of sudden cardiac death (SCD) in patients with heart failure. However, identifying which high-risk patients may benefit from an ICD is sometimes problematic.
|
07/2006 |
11-6 |
Peripartum Cardiomyopathy
By MOHAMMAD I ZIA, MD, FRCPC, and GORDON MOE, MD, FRCPC
Peripartum cardiomyopathy (PPCM) is a rare cardiac condition associated with significant morbidity and mortality. It is an idiopathic form of dilated cardiomyopathy that presents in late pregnancy or post-delivery.
|
06/2006 |
11-5 |
Cell Therapy Following Acute Myocardial Infarction: Do Recent Clinical Trial Results Still Warrant Enthusiasm?
By MICHAEL R. WARD, BSc, DUNCAN J. STEWART, MD; and MICHAEL J.B. KUTRYK, MD, PhD
With advancements in pharmacologic and mechanical reperfusion strategies, survival following myocardial infarction (MI) has greatly improved. Strategies to shorten the time from symptom-onset to treatment in M I have been the focus of considerable study.
|
05/2006 |
11-4 |
Recommendations for the Management of Dyslipidemia and the Prevention of Cardiovascular Disease: 2006 Update
By RAYMOND H.M. CHAN, MD, and BETH L. ABRAMSON, MD
There is ongoing evidence that lipid lowering is important in reducing cardiovascular risk. The first Canadian guidelines for dyslipidemia management were released in 1988 by the Working Group on Hypercholesterolemia and other Dyslipidemias,1 with subsequent updates in 20002 and 2003.
|
04/2006 |
11-3 |
Sensitivity to Antiplatelet Agents in Patients with Acute Coronary Syndromes: Role of Desensitization Therapy
By ANTONIO ROCCA MD, PhD, and GORDON MOE, MD
The importance of aspirin and other antiplatelet agents is well-established for several indications, ranging from acute coronary syndromes (ACS) to percutaneous coronary intervention.
|
03/2006 |
11-2 |
Non-ST Segment Elevation Myocardial Infarction:
Risk Stratification and Early Management
By SAAD ALHASANIAH, MD, and GORDON MOE, MD
Non-ST segment elevation myocardial infarction (NSTEMI) is a common problem encountered in clinical practice. A common question for the clinician is whether patients with NSTEMI would benefit from early intervention as compared to medical therapy, or if intervention should be reserved for unstable patients or those with a positive predischarge stress test.
|
02/2006 |
11-1 |
Recombinant Human Brain Natriuretic Factor
(rhBNP) Therapy for the Treatment of Acute
Decompensated Heart Failure
By WARREN T. BALL, MD, MSC, and GORDON MOE, MD, FRCPC
Heart failure (HF) is associated with significant morbidity and mortality. Despite advances in the treatment of chronic HF, few, if any, novel therapies have been developed that successfully alleviate symptoms or improve outcomes in patients with acute decompensated HF (ADHF).
|
12/2005 |
10-10 |
Anemia and Heart Failure: Prevalence, Prognosis, Pathophysiology, and Treatment
By GAVIN Y. OUDIT, MD, PhD, and GORDON MOE, MD, FRCPC
Heart failure (HF) is a disease associated with a poor prognosis. Anemia is common in patients with diastolic and systolic HF and is one of the many predictors of poor prognosis. Epidemiologic studies indicate that the prevalence of anemia varies from 10%-50% and increases with severity of HF, declining renal function, and increasing age.
|
11/2005 |
10-9 |
Smoking Cessation
By NANCY REBELLATO, BSCPHM, and BETH ABRAMSON, MD
Cigarette smoking is the leading contributor to premature death, illness, and healthcare expense. Smoking cessation reduces the risk, slows the progression of tobacco-related diseases, and increases life expectancy.
|
10/2005 |
10-8 |
Echocardiographic Evaluation of Heart Failure Patients for Cardiac Resynchronization Therapy: A Practical Primer
By CHI-MING CHOW, MD, CM, MSC, FRCPC, FACC
Despite major advances in medical therapy, morbidity and mortality remain high among patients diagnosed with heart failure (HF). In Canada, the average in-hospital mortality per index admission averaged 9.5 deaths/100 hospitalized cases between 1997 and 2000.
|
09/2005 |
10-7 |
Left Ventricular Thrombus:
Diagnosis, Prevention, and Management
By IAN M. BILLINGSLEY, MD, FRCP, and HOWARD LEONG-POI, MD, FRCP
Left ventricular thrombus (LVT) is a well-recognized complication of acute myocardial infarction (AMI) and congestive heart failure (CHF) due to severely impaired LV systolic function.
|
08/2005 |
10-6 |
Statin Therapy for Valvular Aortic Stenosis: Opportunities and Challenges
By GAVIN Y. OUDIT, MD, PHD, and CHI-MING CHOW, MDCM, MSC, FRCPC
Calcification of the aortic valve is the third leading cause of heart disease in adults. While indications for aortic valve replacement are well established, potential medical interventions to treat valvular aortic stenosis (VAS) have only recently been explored.
|
05/2005 |
10-5 |
Cardiovascular Risks of Cyclooxygenase-2 inhibitors
By FILIO BILLIA, M.D., Ph.D., and GORDON MOE, M.D.
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat chronic pain and inflammation in patients with osteoarthritis and other musculoskeletal disorders. In the United States, these disorders affect 15 to 30 million people, aged between 50 to 60 years of age.
|
04/2005 |
10-4 |
The Role of Echocardiography in the Diagnosis and Management of Acute Pulmonary Embolism
By MARC ALLARD MD, FRCPC, and HOWARD LEONG-POI MD, FRCPC
The diagnosis of an acute pulmonary embolism is often difficult to make since many of the clinical symptoms can be confused with other acute pulmonary or cardiac disorders.
|
03/2005 |
10-3 |
The Assessment and Management of Perioperative Cardiac Risk in Patients undergoing Non-cardiac Surgery
By SHELDON M. SINGH, MD, AND GORDON W. MOE, MD, FRCPC
Of the 26 million North Americans undergoing noncardiac surgery every year, between 1% to 5% suffer a major cardiovascular event. Managing this risk is a common challenge encountered by surgeons, anesthetists, internists, and cardiologists and the challenge is augmented by the increasing frequency of older patients with chronic illnesses undergoing major surgery.
|
02/2005 |
10-2 |
Universal Healthcare: Equal for all?
Socioeconomic Differences in Post-myocardial
Infarction Care and Outcomes in Canada
By HARINDRA WIJEYSUNDERA MD, FRCP, and GORDON MOE MD, FRCP
Canadians strongly support the core values on which our healthcare system is premised equity, fairness and solidarity. These values are tied to their understanding of citizenship. Canadians consider equal and timely access...on the basis of need as a right of citizenship, not a privilege of status or wealth.... Medicare is a worthy national achievement, a defining aspect of our citizenship and an expression of social cohesion.
In November 2002, Roy Romonov gave the above description in the Commission on the Future of Health Care in Canada.
|
01/2005 |
10-1 |
Complications of Intra-aortic Balloon Pump: Can we prevent them?
By SANJIT JOLLY, MD, FRCP and GORDON MOE, MD, FRCP
The complications of intra-aortic balloon pump (IABP) often occur in critically-ill patients who are least able to tolerate them. This issue of Cardiology Rounds presents several cases illustrating the complications of IABP and describes the incidence of these complications based on a literature review.
|
12/2004 |
9-10 |
Role of Anticoagulation in Patients with Atrial Fibrillation
By GILLIAN NESBITT, MD, and IQWAL MANGAT, MD
Atrial fibrillation (AF) is the most common sustained arrhythmia. It is estimated that >200,000 Canadians suffer from this rhythm disturbance and, in 2000, 555 hospitalizations per 100,000 population in Canada were attributed to AF or atrial flutter.
|
11/2004 |
9-9 |
HIV and Coronary Artery Disease: A Heart to HAART Discussion
By PAUL GALIWANGO, MD, GORDON MOE, MD
Health Canada estimates that there were approximately 56,000 people living with the human immunodeficiency virus (HIV) in Canada at the end of 2002, approximately one-third of whom were undiagnosed.
|
10/2004 |
9-8 |
Heart Failure as a Neuroendocrine Syndrome:
The role of natriuretic peptides in diagnosis, prognosis, and management
By RAYMOND YAN, MD and GORDON MOE, MD
Increasing recognition of heart failure (HF) as a neuroendocrine syndrome has produced remarkable progress in its management, including the development of many contemporary medical therapies with favourable neurohormonal-modulatory properties that reduce mortality and morbidity.
|
08/2004 |
9-7 |
The Role of Continuous ECG Monitoring in the
Management of Acute Coronary Syndromes
By ANDREW T. YAN, MD, and SHAUN G. GOODMAN, MD, MSC
Accurate diagnosis and risk stratification are critical in the management of acute coronary syndromes (ACS) by enabling clinicians to appropriately triage patients and target pharmacological and interventional therapies. The standard 12-lead electrocardiogram (ECG) is a well-established tool in both the diagnosis and prognostication of ACS.
|
06/2004 |
9-6 |
Coronary Computed Tomographic Angiography
By TEJ SHETH, MD, FRCPC; TARANG SHETH, MD, FRCPC; and BRADLEY STRAUSS, MD, PhD
Catheter-based coronary angiography has played a central role in the evolution of cardiology since it was first developed over 50 years ago.
|
05/2004 |
9-5 |
Anticipating Acute Coronary Syndromes:
Identifying Vulnerable Plaque in Vulnerable Patients
By TEJ SHETH, MD, FRCPC, and BRADLEY STRAUSS, MD, PhD, FRCPC
The manifestations of atherosclerotic coronary artery disease (CAD) can be classified into those that arise from stable plaques and those that arise from unstable plaques.
|
04/2004 |
9-4 |
Is an Open Artery Enough? Assessment and Optimization of Myocardial Perfusion in ST-Elevation MI
By HARINDRA WIJEYSUNDERA, MD, and WARREN CANTOR, MD, FRCP
For over two decades, the cornerstone of therapy for acute myocardial infarction (MI) has been the restoration of flow in the infarct-related artery (IRA), based on the open artery hypothesis.
|
03/2004 |
9-3 |
The Long QT Syndrome
By FAYEZ BOKHARI, MD, FRCPC, and PAUL DORIAN, MD, FRCPC
A 27-year-old patient is referred for the assessment of multiple episodes of loss of consciousness. She began to have syncope at about age 19, initially once or twice a year, but 5 times in the past year. A neurologist diagnosed seizure disorder and placed her on anti-seizure drugs.
|
02/2004 |
9-2 |
Refractory Angina Pectoris: A Therapeutic Challenge
By ADEL HAMAD, MD, and CHI-MING CHOW, MD
Since the advent of coronary artery bypass graft (CABG) surgery in 1966 and percutaneous transluminal coronary angioplasty (PTCA) in 1977, there has been significant progress in the field of coronary revascularization.
|
01/2004 |
9-1 |
Stem Cells for Myocardial Revascularization and Regeneration
By NEIL P. FAM, MD, MSc, and DUNCAN J. STEWART MD, FRCPC
Early reperfusion of the infarct-related artery (IRA) improves both early and late outcomes in patients with acute myocardial infarction (MI). However, adverse left ventricular (LV) remodeling and the subsequent development of heart failure(HF) remain important causes of morbidity and mortality, as well as significant cost to the healthcare system.
|
12/2003 |
8-10 |
Drug-eluting stents for the treatment
of coronary artery disease. Part 4: New results from clinical trials and future directions.
By MICHAEL J. B. KUTRYK, MD, PhD, FRCPC
The implantation of drug-eluting stents has become the percutaneous treatment of choice for many patients with coronary lesions. In 2002, two issues of Cardiology Rounds reviewed the development and early trials of drug-eluting stents for the treatment of coronary artery disease.
Because several important new multicentre clinical trials with updated information have
|
11/2003 |
8-9 |
Drug-eluting stents for the treatment of coronary artery disease
Part 3: New results from clinical trials
By MICHAEL J. B. KUTRYK, MD, PhD, FRCPC
Since the first reports of the success of drug- eluting stents for prevention of in-stent restenosis by Sousa et al and Rensing et al in 2001, the implantation of drug-eluting stents has become the percutaneous treatment of choice for many coronary lesion subsets.
|
10/2003 |
8-8 |
Cardiovascular syndromes associated with cocaine use
By ADEL HAMAD, B.MED.SC., M.D., and CHI-MING CHOW, M.D.C.M., M.SC., F.R.C.P.C.
Cocaine is one of the most commonly used illicit drugs among people seeking care in hospital emergency departments or drug-treatment centres. In addition, it is the most frequent cause of drug-related deaths reported by medical examiners.
|
08/2003 |
8-7 |
Troponin: A window for assessing the high cardiovascular mortality in chronic renal failure
By ANDREW YAN, M.D., DAVID H. FITCHETT, M.D.
Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD) and accounts for about 50% of overall mortality.
|
07/2003 |
8-6 |
Prevention of radiocontrast-induced nephropathy
By JOHN JANEVSKI, MSC, MD, FRCPC, and GORDON MOE, MD, FRCPC
Radiocontrast-induced nephropathy (RCIN) is a common and important complication of coronary angiography and percutaneous coronary intervention (PCI).
|
05/2003 |
8-5 |
Bedside right heart catheterization and invasive monitoring
By AFSANEH POURDOWAT, MD, and GORDON MOE, MD
In 1929, Werner Forssmann first demonstrated that a catheter could be advanced safely into the human heart from a peripheral vessel; he did this by advancing a urethral catheter into his own heart.
|
04/2003 |
8-4 |
Papillary muscle rupture post-myocardial infarction
By SANJIT JOLLY, MD and STUART HUTCHISON, MD, FRCPC
Among the mechanical complications of myocardial infarction (MI), papillary muscle rupture
(PMR) poses a worthy challenge to the clinician. When unrecognized, it is lethal in nearly all patients; however, when it is promptly recognized and surgically corrected, survival is possible in the majority of cases.
|
03/2003 |
8-3 |
Valvular heart disease in pregnancy
By AFSANEH POURDOWLAT, MD
Management of pregnancy in patients with valvular heart disease (VHD) continues to pose a challenge to clinicians. VHD may have a significant impact on fetal and maternal health during pegnancy, abour, and delivery.
|
02/2003 |
8-2 |
Diastolic heart failure
By SALEM ALKAABI, M.D., and GORDON MOE, M.D.
Congestive heart failure (HF) may be considered a condition in which cardiac output is not adequate to meet the metabolic needs of the body either at rest, or during exercise. It is usually accompanied by an increase in cardiac filling pressure and/or circulating volume.
|
01/2003 |
8-1 |
Primary angioplasty in acute myocardial infarction
HAHN HOE KIM, MD and WARREN CANTOR, MD
The patient who suffers an acute ST-elevation myocardial infarction (STEMI) continues to present a difficult challenge to the treating physician.
|
12/2002 |
7-10 |
Bypass surgery versus PCI for multivessel coronary artery disease: Competing or complimentary strategies?
By MARK S. HANSEN, MD; SHAUN GOODMAN, MD, FRCPC;
WARREN J. CANTOR, MD, FRCPC
Coronary artery bypass graft surgery (CABG), in comparison to medical therapy, reduces mortality in patients with high-risk coronary anatomy and/or ventricular dysfunction.
|
11/2002 |
7-9 |
The emerging role of cardiovascular MRI in the evaluation of cardiovascular disorders
FAYEZ BOKHARI, MD, FRCPC; LOUIS WU, MD, FRCPC; and CHI-MING CHOW, MD, MSC, FRCPC
Cardiovascular magnetic resonance imaging (CVMRI) is a rapidly emerging field in cardiovascular medicine that has enormous potential.
|
10/2002 |
7-8 |
Cardiogenic shock from right ventricular infarction
CHRISTOPHER OVERGAARD, M.D., and DAVID FITCHETT, M. D.
Cardiogenic shock associated with right ventricular infarction (RVI) is a challenging clinical entity with important therapeutic implications.
|
08/2002 |
7-7 |
Drug-eluting stents for the treatment of coronary artery disease
Part 2: Trials with rapamycin and other coating agents
MICHAEL J.B. KUTRYK, MD, PhD, FRCPC
Despite their success, coronary stenting procedures may be limited by subsequent in-stent
restenosis.
|
06/2002 |
7-6 |
Drug-eluting stents for the treatment of coronary artery disease Part 1: Background and trials with paclitaxel
MICHAEL J.B. KUTRYK, M.D., Ph.D., FRCPC
The acceptance and widespread clinical application of coronary stents is the most important advance in interventional cardiology since the introduction of balloon angioplasty 20 years ago.
|
05/2002 |
7-5 |
Carcinoid heart disease: The heart is part of the whole body
AJAI PASRICHA, MD and TREVOR ROBINSON, MD
Carcinoid tumours are rare neoplasms that have unique and challenging cardiovascular manifestations. The incidence of carcinoid tumours is about 1.5/100,000 in the general population and it is estimated that about 30% of affected individuals go on to develop carcinoid syndrome.
|
04/2002 |
7-4 |
The role of transesophageal echocardiography
in the cardioversion of atrial fibrillation
By ANDREW T. YAN MD, CHI-MING CHOW MD MSC FRCPC
Atrial fibrillation (AF) is the most common sustained arrhythmia in the general population, and its incidence rises with increasing age.
|
03/2002 |
7-3 |
Endothelial dysfunction/Erectile dysfunction:
Common mechanisms, common management
by JUAN CARLOS MONGE MD
Endothelial dysfunction, considered by many to be at the root of atherosclerotic vascular disease, shares many common risk factors with erectile dysfunction.
|
02/2002 |
7-2 |
Identifying Patients for High Risk Primary Prevention: The Role of Electron Beam CT Calcium Scoring
TEJ SHETH, MD, ROBERT J. CHISHOLM, MD.
Electron beam computed tomography (EBCT) offers a non-invasive, validated assessment of the extent of atherosclerosis in the coronary tree.
|
01/2002 |
7-1 |
Angiotensin receptor blockade in the treatment of heart failure: New data from the Valsartan Heart Failure Trial (Val-HeFT)
GORDON MOE, MD
Inhibition of the renin-angiotensin-aldosterone system remains the most important strategy in the treatment of heart failure.
|
12/2001 |
6-10 |
Natriuretic peptides in heart failure:
Potential role in diagnosis and therapy
TEJ SHETH, MD and GORDON W. MOE, MD
The natriuretic peptides have been the subject of intense research for over two decades.
|
11/2001 |
6-9 |
The Brugada syndrome: A new malignant cardiac channelopathy
FAYEZ BOKHARI, MD, and DAVID NEWMAN, MD, FRCPC, FACC
The Brugada syndrome was first described in 1986, although there is an earlier, less-cited, description.
|
10/2001 |
6-8 |
Novel risk factors for coronary artery disease
SALEEM KASSAM, MD, and DUNCAN STEWART, MD
With the rise in the prevalence of coronary artery disease (CAD), predicting and modifying the risks associated with CAD have gained importance in modern medicine.
|
08/2001 |
6-7 |
Percutaneous coronary intervention in the
management of coronary artery disease
FAYEZ BOKHARI, MD and WAYNE BATCHELOR, MD
Modern invasive cardiology stems from a legacy dating back more than a century and a half.
|
07/2001 |
6-6 |
Angiogenesis: An emerging technology for
the treatment of coronary artery disease
MICHAEL J.B. KUTRYK, MD, PHD; SALEEM A. KASSAM, MD, MCE; and DUNCAN J. STEWART, MD
Ischemic heart disease is the major cause of death in adults in most developed and many developing countries and is now the most common cause of death worldwide.
|
06/2001 |
6-4 |
Resynchronization therapy: the arrival of
a new cardiac device indication
DAVID NEWMAN, MD
In general, physicians using implanted device therapy have paid relatively little attention to the exact effects of pacing on left ventricular mechanical function.
|
03/2001 |
6-3 |
Catheter-based reperfusion for acute myocardial infarction
WARREN CANTOR, MD, and JACEK LINDE, MD
Despite tremendous progress in the development of newer thrombolytic agents, morbidity and mortality in the acute phase of myocardial infarction (MI) remains high.
|
02/2001 |
6-2 |
Hypertrophic cardiomyopathy in 2001
GEOFF PULEY, MD, ROBERT CHISHOLM, MD
Hypertrophic cardiomyopathy is a clinically heterogeneous disease caused by a wide variety of mutations in genes encoding cardiac sarcomeric proteins.
|
01/2001 |
6-1 |
The emerging role of angiotensin receptor
blockers in the therapy of chronic heart failure
GORDON MOE, MD
Blockade of the renin-angiotensin-aldosterone system (RAAS) is the most established therapeutic approach in the management of patients with heart failure.
|
12/2000 |
5-8 |
Stress echocardiography
PAUL CHONG, MD and ANATOLY LANGER, MD
Noninvasive tests play a pivotal role in everyday cardiology practice in risk-stratifying patients for adverse cardiac events.
|
11/2000 |
5-7 |
Intra-aortic balloon counterpulsation in the CCU
GEOFF PULEY, MD and STUART J. HUTCHISON, MD
For the treatment of a variety of conditions seen in the CCU, intra-aortic balloon counterpulsation (IABC) is an effective intervention.
|
10/2000 |
5-6 |
Failed thrombolysis following
acute myocardial infarction
LORNE E. GOLDMAN, MD, WARREN J. CANTOR, MD
Clinical outcome following thrombolytic therapy for acute myocardial infarction (AMI) is strongly associated with patency of the infarct-related artery.
|
08/2000 |
5-5 |
In-stent restenosis:new approaches to an old problem
BRADLEY STRAUSS, MD, and SALEEM KASSAM, MD
Intracoronary stents have an unequivocal role in the realm of percutaneous coronary intervention. By preventing early complications and attenuating restenosis, they have been widely adopted by the cardiology community.
|
06/2000 |
5-4 |
Implantable left ventricular assist devices
MICHAEL HEFFERNAN M.D, Ph.D, ANATOLY LANGER M.D.
Congestive heart failure (CHF) is a major cause of morbidity and mortality in Canada. The syndrome is characterized by a reduction in cardiac output and ineffective emptying of the left ventricle during systole.
|
05/2000 |
5-3 |
HIV and the heart
MICHAEL HEFFERNAN, MD, PhD, BETH L. ABRAMSON, MD
HIV infection is an increasingly important health problem in developed and Third World countries.
|
04/2000 |
5-2 |
Who gets an invasive electrophysiological study for ventricular arrhythmias in 2000?
ARNOLD PINTÉR, MD, DAVID NEWMAN, MD, FRCPC
Programmed electrical stimulation of the ventricle is often regarded as the gold standard for risk stratification in patients susceptible to malignant ventricular arrhythmias and sudden cardiac death.
|
02/2000 |
5-1 |
Diastolic dysfunction
HOWARD LEONG-POI, MD, STUART HUTCHISON, MD
Diastolic dysfunction, a syndrome characterized by impaired ventricular filling, is increasingly recognized as an important cause of symptoms and as a prognostic indicator in many patients with congestive heart failure.
|
06/1999 |
4-6 |
Management of hypertension in the late 1990s
JUAN CARLOS MONGE, MD
The status of hypertension management in this decade allows us some grounds for optimism. We have entered an accelerated phase of large randomized clinical trials that have provided, or are in the process of investigating, the answers to important clinical questions in hypertension.
|
05/1999 |
4-5 |
Coronary artery bypass surgery for congestive heart failure: An
evidence-based approach
I. MANGAT MD, MICHEAL R. FREEMAN MD
Despite ongoing advances in medical care, congestive heart failure (CHF) continues to be a leading cause of cardiovascular morbidity and mortality.
|
04/1999 |
4-4 |
Preoperative cardiac risk assessment for vascular surgery: Can it make a difference?
K. NANTHAK UMAR, MD and MICHEAL R. FREEMAN, MD
Angiographically significant coronary artery disease (CAD) is common among patients with aortic and peripheral vascular disease.
|
03/1999 |
4-3 |
Be still my beating heart: Panic disorder and the cardiologist
FARIDA M. JEEJEEBHOY, MD and DAVID M. NEWMAN, MD
Panic disorder is a common condition with symptoms that can masquerade as a primary cardiovascular disorder.
|
02/1999 |
4-2 |
The role of angioplasty when thrombolysis fails
S. DOUGLAS LEE, MD, DAVIS H. FITCHETT, MD, ROBERT J. CHISHOLM, MD
The restoration of normal coronary artery blood flow early after the onset of acute myocardial infarction (MI) is associated with an improvement of both survival and left ventricular function.
|
01/1999 |
4-1 |
Non-pharmacological treatment of atrial fibrillation
PAUL DORIAN, MD
Atrial fibrillation is the most common clinical arrhythmia and may be precipitated by various clinical risk factors.
|
11/1998 |
3-4 |
Use of implantable cardioverter defibrillators: From trials to practice
PHILIP JONG, MD and PAUL DORIAN, MD
Patients with sustained ventricular tachycardia or ventricular fibrillation are at high risk of sudden cardiac death.
|
10/1998 |
3-3 |
Role of inflammation and infection in atherosclerotic heart disease
PHILIP JONG, MD and JUAN CARLOS MONGE, MD
Ample evidence now exists to suggest a role of inflammation and infection in the development and progression of atherosclerotic heart disease.
|
08/1998 |
3-2 |
After HERS: What is the role of HRT in the prevention of CAD in women?
STUART HUTCHISON, MD and HOWARD LEONG-POI, MD
Cardiovascular disease coronary artery disease (CAD), cerebrovascular disease, and aneurysm remains the leading cause of death in women in North America, accounting for 45% of all deaths in females in the U.S. in 1994.
|
06/1998 |
3-1 |
New directions in thrombolytic therapy
WAYNE HO PING KONG, MD, FRCPC, SHAUN GOODMAN, MD, FRCPC
The most frequent cause of acute myocardial infarction is occlusive thrombus of the coronary arteries.
|
12/1997 |
2-7 |
Viable but Dysfunctional Myocardium: Pathophysiology, Detection, and Treatment
HOWARD LEONG-POI,MD and MICHAEL R. FREEMAN, MD
One of the greatest determinants of survival in patients with coronary artery disease (CAD) is left ventricular (LV) function.
|
11/1997 |
2-6 |
Serum troponin in the risk stratification of acute coronary syndromes
DAVID FITCHETT, MD
The risk stratification of patients with chest pain and no ECG evidence of ST-segment elevation allows triage of patients to the most appropriate level of care.
|
05/1997 |
2-5 |
Angiotensin-converting Enzyme Inhibitors and Endothelial Function
JUAN CARLOS MONGE, MD
We have now become quite accustomed to the fact that we can intervene with pharmacological therapy to modify the function of many organs or tissues.
|
04/1997 |
2-4 |
Transmyocardial Laser Revascularization
IQWAL MANGAT, MD, DUNCAN J . STEWART, MD
Revascularization of ischemic myocardium is classically achieved by improving perfusion through epicardial coronary arteries.
|
03/1997 |
2-3 |
Transesophageal Echocardiographic-Guided Cardioversion of Atrial Fibrillation
F. AL-BAKSHY, MD, S. HUTCHISON, MD
Atrial fibrillation, the most common sustained tachyarrhythmia is characterized by disorganized electrical and mechanical activity of the atria.
|
02/1997 |
2-2 |
Stress Cardiolite Imaging: Do The Results in Clinical Practice Meet Our Expectations?
MICHEAL FREEMAN, MD
Stress myocardial perfusion imaging fulfills an important role in the physicians assessment of patients with known or suspected coronary artery disease.
|
01/1997 |
2-1 |
Ventricular Assist Devices
SUZANNA MAK, MD, GORDON MOE, MD
The term ventricular assist device, or VAD, describes any of a variety of mechanical blood pumps employed singly to replace the function of either the right or left ventricle.
|
12/1996 |
1-9 |
Primary Pulmonary Hypertension
ANNA WOO, MD, DUNCAN J. STEWART, MD
Primary pulmonary hypertension (PPH) remains one of medicines more difficult challenges since it is a rare disease, its causes are obscure, its natural history is unclear, and there are few treatment options.
|
11/1996 |
1-8 |
Thrombolysis or PTCA for Acute Transmural Myocardial Infarction
IQWAL MANGAT MD, MICHAEL FREEMAN MD, FRCP
Early and sustained infarct related artery (IRA) patency contributes to improved left ventricular function and outcome after myocardial infarction.
|
10/1996 |
1-7 |
The Role of Low Molecular Weight Heparin in the Management of Ischemic Heart Disease
SHAUN GOODMAN, MD
There is now extensive evidence implicating partial or complete thrombotic occlusion of the coronary artery in the pathogenesis of unstable angina and acute myocardial infarction.
|
09/1996 |
1-6 |
Assessment of the Delta Wave: Wolves in the 90s
MICHAEL GEIST, MD and DAVID NEWMAN, MD
When Wolff, Parkinson and White first described the syndrome that carries their name in 1930, it was thought to be a sign of good health.
|
08/1996 |
1-5 |
Homocysteine and Vascular Disease
STEVEN E.S. MINER, MD, DAVID E.C. COLE, MD, PhD and DUNCAN J. STEWART, MD
Homocysteine is a naturally occurring, sulfur- ontaining amino acid. Continuously formed and catabolized in vivo, its metabolism is dependent on a complex interaction of genetics and physiology.
|
07/1996 |
1-4 |
Vitamin E in Cardiovascular Disease
IQWAL MANGAT, MD and SHAUN GOODMAN, MD
Vitamin E was first introduced in 1946 as a therapeutic agent for angina. At that time, it was felt to significantly reduce angina in over 90% of patients studied.
|
06/1996 |
1-3 |
Acute ischemic syndromes and new antithrombotic agents
S. CONNORS, MD, DPhil and A. LANGER, MD
Plaque rupture and coronary thrombus formation is critical in the pathogenesis of acute ischemic syndromes. Despite successful pharmacologic therapy directed at thrombolysis, antithrombotic treatment remains suboptimal.
|
05/1996 |
1-2 |
The Role of ß-Blockers in Congestive Heart Failure
B. SONNENBERG and GORDON W. MOE, MD
Congestive heart failure (CHF) is a common medical disorder, affecting approximately 1% of the adult population.
|
04/1996 |
1-1 |
Coronary Angioplasty vs. Coronary Bypass Surgery
WARREN J. CANTOR, MD, and ROBERT J . CHISHOLM, MD, FRCP
Both percutaneous coronary angioplasty (PTCA) and coronary artery bypass graft surgery (CABG) are highly effective in reducing symptoms of angina as well as improving exercise capacity and quality of life in patients with coronary artery disease.
|
Total: 112 |
|
